PureTech Health (LON:PRTC) Trading Up 14% - Here's Why

Key Points

• PureTech Health shares rose by 14% in mid-day trading, reaching a high of GBX 123.80 ($1.68) compared to the previous close of GBX 106.40 ($1.44).
• Insider Bharatt Chowrira purchased 167,739 shares, indicating confidence in the company's prospects, with corporate insiders owning 13.13% of the stock.
• PureTech Health focuses on developing medicines for diseases related to the nervous, gastrointestinal, and immune systems, including a microbiome-based drug-discovery platform.

PureTech Health plc (LON:PRTC - )'s share price was up 14% during mid-day trading on Friday . The company traded as high as GBX 123.80 ($1.68) and last traded at GBX 121.30 ($1.64). Approximately 2,367,023 shares traded hands during mid-day trading, an increase of 218% from the average daily volume of 745,025 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Stock Up 14.2%

The business's 50 day moving average is GBX 129.64 and its 200-day moving average is GBX 129.95. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The company has a market cap of £293.65 million, a PE ratio of 714.71 and a beta of 1.02.

Insider Transactions at PureTech Health

In other news, insider Bharatt Chowrira purchased 167,739 shares of the firm's stock in a transaction that occurred on Thursday, July 3rd. The stock was bought at an average price of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is owned by corporate insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.